Abstract: PDGF-D, a new member of the PDGF/VEGF family of growth factors, is described, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

Abstract: The present invention provides for a non-naturally occurring binding protein comprising an amino acid sequence capable of binding to a CCG regulatory sequence and an amino acid sequence which forms a transcription activation region. In particular the invention comprises a sequence selected from the group consisting of an AP2 domain of SEQ. I.D. Nos. 13, 15, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, and 95. When these proteins are overexpressed in a plant the plant exhibits increased tolerance to environmental stresses such as cold, freezing, drought or high salinity.

Abstract: Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line. MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein.

Abstract: This invention is directed to polynuclectides encoding novel species-specific P. vivax malarial peptide antigens which are proteins or fragments of proteins secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against those antigens. The peptide antigens, monoclonal antibodies, and/or polyclonal antibodies are utilized in assays used to diagnose malaria, as well as to determine whether Plasmodium vivax is the species responsible for the infection.

Abstract: In certain aspects, the invention relates to cell delivery compositions comprising a chondrogenic cell and a targeting moiety. Such compositions may be used, for example, in administering a targeted cell therapy to a subject.

Abstract: A micro-electro-mechanical systems (MEMS) based thin-film fuel cells for electrical power applications. The MEMS-based fuel cell may be of a solid oxide type (SOFC), a solid polymer type (SPFC), or a proton exchange membrane type (PEMFC), and each fuel cell basically consists of an anode and a cathode separated by an electrolyte layer. The electrolyte layer can consist of either a solid oxide or solid polymer material, or proton exchange membrane electrolyte materials may be used. Additionally catalyst layers can also separate the electrodes (cathode and anode) from the electrolyte. Gas manifolds are utilized to transport the fuel and oxidant to each cell and provide a path for exhaust gases. The electrical current generated from each cell is drawn away with an interconnect and support structure integrated with the gas manifold. The fuel cells utilize integrated resistive heaters for efficient heating of the materials.

Abstract: This invention relates to a positive electrode for an electrochemical cell or battery, and to an electrochemical cell or battery; the invention relates more specifically to a positive electrode for a non-aqueous lithium cell or battery when the electrode is used therein. The positive electrode includes a composite metal oxide containing AgV3O8 as one component and one or more other components consisting of LiV3O8, Ag2V4O11, MnO2, CFx, AgF or Ag2O to increase the energy density of the cell, optionally in the presence of silver powder and/or silver foil to assist in current collection at the electrode and to improve the power capability of the cell or battery.

Abstract: This invention provides a method of increasing or maintaining the blood supply in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis. This invention provides a method of treating erectile dysfunction in a subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase the blood supply in the subject's penis and thereby treat the subject's erectile dysfunction. This invention provides a method of increasing or maintaining the blood supply in the penis of a subject which comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell under conditions such that the nucleic acid expresses vascular endothelial growth factor so as to thereby increase or maintain the blood supply in the subject's penis.

Abstract: The present invention relates to a novel HLF protein which is a member of the heregulin family. In particular, isolated nucleic acid molecules are provided encoding the human HLF protein. HLF polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of HLF activity. Also provided are diagnostic methods for detecting disorders of the regulation of cell growth and therapeutic methods for treating disorders of the regulation of cell growth.

Abstract: A method of statistical analysis can include receiving data within a first window of a graphical user interface and executing a statistical function over a user-specified portion of the data. Within a second window of the graphical user interface, a result determined from execution of the statistical function can be presented. Interpretation rules can be applied to the result to determine an interpretation of the result. Within a third window of the graphical user interface, the interpretation of the result can be presented. The interpretation can indicate whether the result conforms to the interpretation rules.

Abstract: A method for identifying additive components for polycrystalline metals and materials that enhance grain boundary cohesion and compositions of such materials comprises calculation of an empirical value &Dgr;BAwhich is dependent upon a summation of various energy values associated with the matrix and additives and identifying the additives having a negative value. Formulations of alloys having improved physical properties and their processing steps are also disclosed.

Abstract: This invention provides methods for treating a subject afflicted with atrial tachyarrhythmia and methods for inhibiting the onset of atrial tachyarrhythmia. This invention also provides methods for treating a subject afflicted with exercise-induced or stress-induced cardiac arrhythmia and methods for inhibiting the onset of exercise-induced or stress-induced cardiac arrhythmia.

Abstract: Disclosed herein are novel alleles characterized by polymorphisms in the CAST gene. The alleles may be used to genetically type animals. In a preferred embodiment, the alleles may be used as markers for animal meat quality and/or growth. Methods for identifying such markers, and methods of screening animals to determine those more likely to produce desired meat quality and/or growth and preferably selecting those animals for future breeding purposes are also disclosed.

Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and is derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96.

Abstract: A controlling device having programming which ensures an appliance will be placed into a desired power state. The controlling device transmits a query message to a power monitor associated with the appliance to obtain the current power state of the appliance. If the current power state corresponds to the desired power state, the controlling device inhibits the transmission of a command to the appliance to effect a change in the current power state of the appliance.

Abstract: A system for quantitatively reducing oxide gases. A pre-selected amount of zinc is provided in a vial. A tube is provided in the vial. The zinc and the tube are separated. A pre-selected amount of a catalyst is provided in the tube. Oxide gases are injected into the vial. The vial, tube, zinc, catalyst, and the oxide gases are cryogenically cooled. At least a portion of the vial, tube, zinc, catalyst, and oxide gases are heated.

Abstract: A bacterial &agr;1,2-fucosyltransferase gene and deduced amino acid sequence is provided. The gene is useful for preparing &agr;1,2-fucosyltransferase polypeptide, and active fragment thereof, which can be used in the production of oligosaccharides such as Lewis X, Lewis Y, Lewis B and H type 1, which are structurally similar to certain tumor-associated carbohydrate antigens found in mammals. These product glycoconjugates also have research and diagnostic utility in the development of assays to detect mammalian tumors.

Abstract: The present invention provides for a method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase activity which comprises administering to the subject an amount of a zinc sphingomyelinase inhibitor effective to decrease extracellular zinc sphingomyelinase activity in the subject and thereby treat the subject.

Abstract: This invention relates to electrodes for non-aqueous lithium cells and batteries with silver manganese oxide positive electrodes, denoted AgxMnOy, in which x and y are such that the manganese ions in the charged or partially charged electrodes cells have an average oxidation state greater than 3.5. The silver manganese oxide electrodes optionally contain silver powder and/or silver foil to assist in current collection at the electrodes and to improve the power capability of the cells or batteries. The invention relates also to a method for preparing AgxMnOy electrodes by decomposition of a permanganate salt, such as AgMnO4, or by the decomposition of KMnO4 or LiMnO4 in the presence of a silver salt.

Abstract: This invention relates to a sulfur tolerant, dynamic, compact, lightweight fuel process and system that is capable of converting sulfur bearing carbonaceous fuels to hydrogen rich gases suitable for fuel cells or chemical processing applications. The process and system is based on the AHR and WGS reactions, followed by cleanup of byproduct sulfur-containing gases and carbon oxides that would otherwise poison the fuel cell electrocatalyst. Advantageously, this is accomplished via an ASMS and a methanator or an AWMR. The process and system preferably uses a special sulfur tolerant catalysts and hardware designs that enable the conversion in an energy efficient manner while maintaining desirable performance characteristics such as rapid start-stop and fast response to load change capabilities.